Many currently marketed drugs exert their pharmacological effects by binding to ligand-activated transcription factors and modulating gene expression. One example, are various drugs that target the estrogen receptor to treat breast cancer, osteoporosis and post-menopausal symptoms. Below is a ChIP experiment examining the effects of no drug treatment (C), the natural hormone estrogen (E) and the drugs tamoxifen (T) and raloxifene (R) on recruitment of coactivators (SRC-1 and CBP), Histone Deacetylase Complexes (HDACs) and acetylation of histones associated with the C-myc gene. Which of the following statements are correct based on this data (select all that apply)?

icon
Related questions
Question

Many currently marketed drugs exert their pharmacological effects by binding to ligand-activated transcription factors and modulating gene expression. One example, are various drugs that target the estrogen receptor to treat breast cancer, osteoporosis and post-menopausal symptoms. Below is a ChIP experiment examining the effects of no drug treatment (C), the natural hormone estrogen (E) and the drugs tamoxifen (T) and raloxifene (R) on recruitment of coactivators (SRC-1 and CBP), Histone Deacetylase Complexes (HDACs) and acetylation of histones associated with the C-myc gene. Which of the following statements are correct based on this data (select all that apply)? 

 

Breast
Uterus
ERa
SRC-1
C No Drug
E Estrogen
T Tamoxifen
R Raloxifene
HDAC2
HDAC4
CETRCETR CETRCETR
СВР
ACH
CETRCETR
A. Tamoxifen represses C-myc expression in both breast and uterus
B.
Estrogen promotes acetylation of histones in both the breast and uterus which results in increased expression of C-myc
gene.
C. Raloxifene promotes deacetylation of histones which would inhibit expression of C-myc in both breast and uterus.
D.
Tamoxifen promotes binding of SRC to C-myc promoter in the uterus which will enhance transcription of C-myc in the
uterus
E.
Estrogen promotes binding of CBP in both the breast and uterus which results in increased expression of C-myc gene.
Transcribed Image Text:Breast Uterus ERa SRC-1 C No Drug E Estrogen T Tamoxifen R Raloxifene HDAC2 HDAC4 CETRCETR CETRCETR СВР ACH CETRCETR A. Tamoxifen represses C-myc expression in both breast and uterus B. Estrogen promotes acetylation of histones in both the breast and uterus which results in increased expression of C-myc gene. C. Raloxifene promotes deacetylation of histones which would inhibit expression of C-myc in both breast and uterus. D. Tamoxifen promotes binding of SRC to C-myc promoter in the uterus which will enhance transcription of C-myc in the uterus E. Estrogen promotes binding of CBP in both the breast and uterus which results in increased expression of C-myc gene.
Expert Solution
steps

Step by step

Solved in 3 steps

Blurred answer